pharmaceutical investing Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE in HR+, HER2- Metastatic Breast Cancer
pharmaceutical investing MacroGenics Provides Update on Corporate Progress and 2017 Financial Results
Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations
pharmaceutical investing Cascadian Therapeutics Gets Pediatric Investigation Plan Waiver for Lead Candidate
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
